Biotherapeutics play a critical role in the treatment of human diseases and their market is expanding rapidly. Most biotherapeutics are expressed as recombinant glycoproteins where glycosylation controls properties such as immunogenicity, stability and bioactivity. Thus, glycosylation can directly affect the drug quality, safety and efficacy and must be adequately analyzed and controlled throughout the R&D and manufacturing processes of the drug. Lectin microarrays are very promising as high throughput strategy for assessing glycan patterns of biotherapeutics since lectins can recognize selectively glycan epitopes. We want to develop with GLYCODIAG, a company specialized in glycoprofiling, an array to detect the major undesirable glycanic structures in biotherapeutics and to allow real-time monitoring and control. A panel of solely recombinant lectins, novel strategies for biomolecules conjugation and array immobilization will be elaborated prior validation on model glycoproteins.